BOS-342

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameBOS-342
Drug Alias NamePRS-342BOS-342PRS-342/BOS-342
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionImmunologic cytotoxicityTumor necrosis factor receptor superfamily member 9 agonistsWnt signalling pathway inhibitors +[5] 
TargetsTumor necrosis factor receptor superfamily member 9Glypican-3
Therapy Area/IndicationsSolid tumoursCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPieris Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesPieris PharmaceuticalsBoston Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A